Corcept Therapeutics Reports Strong Q2 Earnings Driven by LIFYORLI Launch
Corcept Therapeutics (NASDAQ:CORT) reported second-quarter revenue of $256.1 million for the period ending June 30, a 32% increase from the prior year. The growth was driven primarily by its Cushing's syndrome business and the successful launch of LIFYORLI, an ovarian cancer therapy that contributed $47.6 million in sales during its first quarter on the market. The company raised its full-year revenue guidance to a range of $1.1 billion–$1.2 billion due to strong performance across both endocrinology and oncology divisions. LIFYORLI has been adopted by over 1,300 patients with more than 1,000 prescribing physicians, supported by coverage policies for over 70% of relevant insured lives. Corcept also announced that the FDA accepted its resubmitted application for relacorilant in Cushing's syndrome and set a December 2026 action date. The company continues to advance pipeline studies across cancer, MASH (metabolic dysfunction-associated steatohepatitis), and ALS.
Tickers: $CORT
Topics: drug_launch pharmaceuticals revenue_growth